×
About 45,258 results

ALLMedicine™ Cirrhosis Center

Research & Reviews  15,097 results

Quantification of liver extracellular volume using dual-energy CT for ruling out high-r...
https://doi.org/10.1016/j.ejrad.2022.110151
European Journal of Radiology; Hong S, Kim JE et. al.

Jan 16th, 2022 - To determine the performance of quantification of liver extracellular volume fraction (fECV) using dual-energy CT (DECT) compared with CT imaging for ruling out high-riskesophageal varices(HRV) in cirrhotic patients. We retrospectively analyzed 22...

Controlling nutritional status score as a new indicator of overt hepatic encephalopathy...
https://doi.org/10.1016/j.clnu.2021.12.036
Clinical Nutrition (Edinburgh, Scotland); Li J, Feng D et. al.

Jan 16th, 2022 - The Controlling Nutritional Status (CONUT) score is designed to assess the immune-nutritional status of patients. Poor nutritional status and inflammation may facilitate the development of hepatic encephalopathy (HE) in cirrhotic patients. However...

Artificial intelligence and the risk for intuition decline in clinical medicine.
https://doi.org/10.14309/ajg.0000000000001618
The American Journal of Gastroenterology; Duarte-Rojo A, Sedjvic E

Jan 15th, 2022 - Artificial intelligence (AI) is revolutionizing big data analytics. In this issue of AJG, Ahn et al. introduce the AI-Cirrhosis-ECG (ACE) score which can grade the electrophysiologic cardiac changes present in patients with cirrhosis. Apart from s...

The COVID-19 pandemic highlights opportunities to improve hepatocellular carcinoma scre...
https://doi.org/10.14309/ajg.0000000000001615
The American Journal of Gastroenterology; Kim NJ, Rozenberg-Ben-Dror K et. al.

Jan 15th, 2022 - We evaluated the COVID-19 pandemic's impact on HCC screening and diagnosis among patients with cirrhosis in the Veterans Health Administration. Rates and predictors of screening and diagnosis were reviewed 9/1/2019-2/29/2020 ("pre-COVID-19",N=94,6...

see more →

Guidelines  38 results

AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients ...
https://doi.org/10.1053/j.gastro.2021.08.015
Gastroenterology O'Shea RS, Davitkov P et. al.

Sep 29th, 2021 - AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.|2021|O'Shea RS,Davitkov P,Ko CW,Rajasekhar A,Su GL,|

AGA Technical Review on Coagulation in Cirrhosis.
https://doi.org/10.1053/j.gastro.2021.09.004
Gastroenterology Intagliata NM, Davitkov P et. al.

Sep 29th, 2021 - AGA Technical Review on Coagulation in Cirrhosis.|2021|Intagliata NM,Davitkov P,Allen AM,Falck-Ytter YT,Stine JG,|

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PORTAL HYPERTENSION.
https://doi.org/10.1016/j.clinre.2021.101767
Clinics and Research in Hepatology and Gastroenterology; Thabut D, Weil D et. al.

Aug 1st, 2021 - Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis/cirrhosis in asymptomatic patients at risk of developing clinically significant portal hypertension (CSPH, defined by a hepatic venous pressure gradient...

Non-invasive diagnosis and follow-up of rare genetic liver diseases.
https://doi.org/10.1016/j.clinre.2021.101768
Clinics and Research in Hepatology and Gastroenterology; Sobesky R, Guillaud O et. al.

Aug 1st, 2021 - Rare genetic liver diseases can result in multi-systemic damage, which may compromise the patient's prognosis. Wilson's disease and alpha-1 antitrypsin deficiency must be investigated in any patient with unexplained liver disease. Cystic fibrosis ...

Non-invasive diagnosis and follow-up of primary biliary cholangitis.
https://doi.org/10.1016/j.clinre.2021.101770
Clinics and Research in Hepatology and Gastroenterology; Corpechot C, Heurgue A et. al.

Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...

see more →

Drugs  600 results see all →

Clinicaltrials.gov  803 results

Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
https://clinicaltrials.gov/ct2/show/NCT02960204

Jan 14th, 2022 - This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined by the central reader assigned to this study). Upon successful ...

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)
https://clinicaltrials.gov/ct2/show/NCT04198805

Jan 13th, 2022 - Background information Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the liver and is defined by evidence of hepatic steatosis (via imaging or histology) and is not due to secondary liver fat accumulat...

Characterization of the Platelet Inflammatory Response in NAFL and NASH
https://clinicaltrials.gov/ct2/show/NCT05128253

Jan 13th, 2022 - Background NonAlcoholic Fatty Liver Disease (NAFLD) is one of the most commonly encountered liver disorders worldwide. NAFLD is a spectrum of liver disease including (i) simple hepatic steatosis also called Non-Alcoholic Fatty Liver (NAFL) and (ii...

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

Jan 12th, 2022 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

Longitudinal Assessment of Muscle Health in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT05184283

Jan 11th, 2022 - The combination of hepatocellular carcinoma and chronic liver disease represents a dual impact on overall metabolism. The major risk factors for chronic liver disease related-hepatocellular carcinoma (HCC) include nonalcoholic fatty liver disease ...

see more →

News  1,510 results

Fatty Liver Disease a Long-COVID Symptom After Severe Cases?
https://www.medpagetoday.com/gastroenterology/generalhepatology/96607

Jan 11th, 2022 - A majority of long-COVID patients who had been hospitalized for severe COVID-19 illness had metabolic (dysfunction)-associated fatty liver disease (MAFLD), a retrospective study from Italy found. In an analysis of 235 patients presenting to a post...

Immunotherapy Approvals Overcome Years of Stagnation in GI Cancers
https://www.onclive.com/view/immunotherapy-approvals-overcome-years-of-stagnation-in-gi-cancers

Dec 22nd, 2021 - Following years of negative clinical trials and little advancement, the incorporation of frontline immunotherapy regimens has reshaped the treatment landscape of several gastrointestinal (GI) malignancies, including upper GI cancers and hepatocell...

Home-Based System Relieves Refractory Ascites in Cirrhosis
https://www.medscape.com/viewarticle/964970

Dec 16th, 2021 - A home-based tunneled peritoneal catheter (PeCa) drainage system provided significant relief for patients with refractory ascites who were not candidates for transjugular intrahepatic portosystemic shunt (TIPS). For these patients, the current sta...

Seizures in a 42-Year-Old Who Left a Hospital Against Advice
https://www.medscape.com/viewarticle/877077

Dec 14th, 2021 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills us...

FIB-4 Could ID Liver Risk in Primary Care
https://www.medscape.com/viewarticle/964659

Dec 13th, 2021 - Fibrosis-4 index (FIB-4) scores are strongly associated with severe liver disease outcomes in a primary care population, both in patients with known chronic liver disease and those without known CLD. The result could help identify patients with CL...

see more →

Patient Education  55 results see all →